New targeted drug combo aims to shrink breast tumors before surgery

NCT ID NCT07305246

Not yet recruiting Disease control Sponsor: First Hospital of China Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called SHR-A1811, alone or with hormone therapy (letrozole), against standard chemotherapy in 120 women with early-stage HR-positive, HER2-low breast cancer. The goal is to see if these combinations can shrink tumors before surgery more effectively or with fewer side effects. Participants will be randomly assigned to one of three treatment groups and receive therapy for 8 cycles before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1811 (a targeted drug) and letrozole (hormone therapy)
What this could lead to: If successful, this could offer a less toxic, targeted neoadjuvant option for HR-positive, HER2-low breast cancer, potentially reducing the need for standard chemotherapy.
What could go wrong: This is an early Phase 2 trial with only 120 participants, so results may not apply broadly. The drug combination may not outperform standard chemo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.